221 related articles for article (PubMed ID: 30675806)
1. Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.
Buxbaum JN; Brannagan T; Buades-Reinés J; Cisneros E; Conceicao I; Kyriakides T; Merlini G; Obici L; Plante-Bordeneuve V; Rousseau A; Sekijima Y; Imai A; Waddington Cruz M; Yamada M
Amyloid; 2019 Mar; 26(1):10-14. PubMed ID: 30675806
[TBL] [Abstract][Full Text] [Related]
2. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.
Monteiro C; Martins da Silva A; Ferreira N; Mesgarzadeh J; Novais M; Coelho T; Kelly JW
Amyloid; 2018 Jun; 25(2):120-128. PubMed ID: 29993288
[TBL] [Abstract][Full Text] [Related]
4. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis.
Beirão JM; Malheiro J; Lemos C; Matos E; Beirão I; Pinho-Costa P; Torres P
Amyloid; 2015 Mar; 22(1):31-5. PubMed ID: 25475560
[TBL] [Abstract][Full Text] [Related]
5. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases.
Beirão JM; Malheiro J; Lemos C; Beirão I; Costa P; Torres P
Amyloid; 2015; 22(2):117-22. PubMed ID: 26096568
[TBL] [Abstract][Full Text] [Related]
6. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
7. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
[TBL] [Abstract][Full Text] [Related]
9. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Sekijima Y
Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
[TBL] [Abstract][Full Text] [Related]
10. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
11. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
13. RE-INTERVENTION IN DE NOVO VITREOUS OPACITIES AFTER PARS PLANA VITRECTOMY IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY TTR VAL30METPORTUGUESE PATIENTS.
Ferreira NN; Cunha Dias DA; Afonso Carvalho RP; Pardal Monteiro Coelho MT
Retin Cases Brief Rep; 2019 Summer; 13(3):273-278. PubMed ID: 28333852
[TBL] [Abstract][Full Text] [Related]
14. Impact of liver transplantation on transthyretin-related ocular amyloidosis in Japanese patients.
Hara R; Kawaji T; Ando E; Ohya Y; Ando Y; Tanihara H
Arch Ophthalmol; 2010 Feb; 128(2):206-10. PubMed ID: 20142544
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
16. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
Socie P; Benmalek A; Cauquil C; Piekarski E; Kounis I; Eliahou L; Rousseau A; Rouzet F; Echaniz-Laguna A; Samuel D; Adams D; Slama MS; Algalarrondo V
Amyloid; 2023 Sep; 30(3):303-312. PubMed ID: 36795029
[TBL] [Abstract][Full Text] [Related]
17. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis.
Ikeda SI; Hineno A; Ichikawa T; Makino M
Amyloid; 2019 Jun; 26(2):99-100. PubMed ID: 31090446
[No Abstract] [Full Text] [Related]
19. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
20. Vitreous opacities in a case of familial amyloidotic polyneuropathy associated with a transthyretin Lys 54.
Imasawa M; Toda Y; Sakurada Y; Imai M; Iijima H
Acta Ophthalmol Scand; 2004 Oct; 82(5):635-7. PubMed ID: 15453875
[No Abstract] [Full Text] [Related]
[Next] [New Search]
